Document is current
Any future updates will be listed below
-
Authors
Kalimuddin, Shirin https://orcid.org/0000-0001-9319-5908
Tham, Christine Y. L. https://orcid.org/0000-0002-2913-7591
Chan, Yvonne F. Z.
Hang, Shou Kit
Kunasegaran, Kamini
Chia, Adeline
Chan, Candice Y. Y.
Ng, Dorothy H. L.
Sim, Jean X. Y.
Tan, Hwee-Cheng
Syenina, Ayesa
Ngoh, An Qi
Hamis, Noor Zayanah
Chew, Valerie
Leong, Yan Shan https://orcid.org/0000-0001-7402-6172
Yee, Jia Xin https://orcid.org/0000-0001-9056-3621
Low, Jenny G. https://orcid.org/0000-0002-3876-2209
Chan, Kuan Rong https://orcid.org/0000-0002-2427-671X
Ong, Eugenia Z.
Bertoletti, Antonio https://orcid.org/0000-0002-2942-0485
Ooi, Eng Eong https://orcid.org/0000-0002-0520-1544
-
Funding
Funding for this research was provided by:
National Research Foundation Singapore (NRF-CRP25-2020-0003)
MOH | National Medical Research Council (MOH-001271-00, MOH-000617-00, MOH-001633-00)
- License Information
-
More Information
Article History
Received: 6 April 2024
Accepted: 4 December 2024
First Online: 10 January 2025
Competing interests
: S.K. and J.G.L. have served in advisory capacities for Takeda on dengue. A.B. is co-founder of T Cell Diagnostics, a company developing virus-specific T cell assays. E.E.O. has served in various advisory capacities for Sanofi Pasteur, Takeda, MSD, Janssen Pharmaceuticals, Novartis and Arcturus Therapeutics on dengue and vaccines. The other authors declare no competing interests.
